TABLE 3.

Characteristics of the 186 patients with ESBL-BSIs

Characteristics	No. (%)a of patients with BSI caused by:				P
	Total (n = 186)	E. coli (n = 104)	K. pneumoniae (n = 58)	P. mirabilis (n = 24)	E. coli vs K. pneumoniae	E. coli vs P. mirabilis	K. pneumoniae vs P. mirabilis
Patient related
Males	107 (57.5)	54 (51.9)	40 (69)	13 (54.1)	0.03	0.84	0.20
Mean age in yr ± SD	54 ± 19	51 ± 20	63 ± 15	45 ± 16	0.01	0.22	<0.001
Underlying disease
Solid tumor	52 (27.9)	21 (20.2)	24 (41.4)	7 (29.1)	0.004	0.33	0.29
Diabetes	50 (26.8)	26 (25)	20 (34.5)	4 (16.7)	0.19	0.38	0.10
Hematological malignancy	45 (24.2)	30 (28.8)	12 (20.6)	3 (12.5)	0.72	0.09	0.38
Liver disease	26 (13.9)	14 (13.5)	9 (15.5)	3 (12.5)	0.71	0.90	0.72
Chronic renal failure	53 (28.4)	32 (30.7)	21 (36.2)	0 (0)	0.47	<0.001	<0.001
Mean days in the hospital ± SD	27 ± 16	24 ± 13	34 ± 20	21 ± 9	0.01	0.35	0.002
Prior exposure to antimicrobial therapy
Cephalosporins	50 (26.8)	25 (24)	18 (31)	7 (29.2)	0.33	0.60	0.86
Quinolones	48 (25.8)	25 (24)	17 (29.3)	6 (25)	0.46	0.92	0.69
Aminoglycosides	19 (10.2)	8 (7.7)	10 (17.4)	1 (4.2)	0.06	0.54	0.11
β-Lactam-β-lactamase inhibitors	34 (18.3)	15 (14.4)	11 (18.9)	8 (33.3)	0.45	0.03	0.16
Infection-related
Health care acquired	168 (90.3)	92 (88.5)	55 (94.8)	21 (87.5)	0.18	0.89	0.24
Source of infection
Unknown	86 (46.2)	41 (39.4)	33 (56.9)	12 (50)	0.03	0.34	0.56
Urinary tract	53 (28.4)	29 (27.9)	15 (25.9)	9 (37.5)	0.78	0.35	0.29
Pancreatico-biliary tract	24 (12.9)	19 (18)	3 (5.2)	2 (8.3)	0.02	0.23	0.58
Surgical wound	29 (10.7)	16 (15.4)	2 (3.4)	2 (8.3)	0.02	0.37	0.35
Lower respiratory tract	6 (3.2)	1 (1)	4 (6.9)	1 (4.2)	0.03	0.25	0.63
Central venous catheter	5 (2.7)	4 (3.8)	1 (1.7)	0 (0)	0.45	0.32	0.51

^aAll values are presented as “no. (%) of patients” except as noted otherwise in column 1.